Small-Cap Plays

Climate-weather intelligence data-as-a-service: LEO satellite constellation providing radio occultation weather data to governments, insurers, ag operators — a direct picks-and-shovels play on disaster-frequency pricing. Q1 FY2026 EPS -$0.37 vs. est. -$0.41 (beat); EPS improvement from -$0.63 YoY is material. Analyst PT $22.50 (reiterated Buy Aug 2026). FY2026 revenue guided $75-85M. HARD FLAGS: Still deeply GAAP-loss ($60M+ op loss); SBC is 10-12% of revenue; SPAC-era dilution overhang; not profitable. This is a high-conviction speculative long ONLY on capitulation washouts. Confirm float/borrow before touching. Stock sub-$15 = coiled IF losses narrow as guided. $12.05 · 20d -7% · -53% vs 1y-hi · $1M/d

Produced-water handling and recycling for Permian Basin operators — hard-infrastructure water logistics at the intersection of drought stress and oilfield operations. Revenue is real and growing (Permian-tied, scale contract model). Stock has traded $8-14 range. CAVEAT: Revenue tied to Permian production volumes; in a risk-off/energy-down tape it trades with crude, not pure water theme. Check most recent quarter for produced-water volumes and customer concentration before entry. Dilution risk moderate — check share count trend. Thesis works best when energy leads (current regime: Energy is a sector leader). $19.72 · 20d +26% · -20% vs 1y-hi · $5M/d

MECHANISM: Florida-concentrated coastal property/casualty insurer. Q2 2026 revenue fell 4.5% to $82.6M; net income dropped and combined ratio rose to 74.3% — metrics worsening even before a major storm event. Valuation discount is structural, not temporary: E&S expansion is not compensating for deteriorating underwriting. Physical risk re-pricing on Gulf/Atlantic coast is the catalyst. EVENT-OPTIONALITY: Borrow may tighten ahead of hurricane season; confirm locate before entry. NOT a grind short — this is a tail-event/volatility play. 2026 pricing softening noted in thesis means the P&L looks OK until it doesn't. $9.49 · 20d -13% · -27% vs 1y-hi · $0M/d

Largest, most liquid US water ETF ($19.7B AUM); holds water distribution, pumps, valves, filtration, metering companies. 10-year annualized return 14.16%. Use as the core directional expression of water infrastructure thesis — not leveraged itself but the liquid, high-conviction long-ETF vehicle. PHO at ~$72-73 (52-week range $63.54-$74.93); near upper range, wait for pullback entry. $70.51

Selects companies deriving majority of revenue from potable/wastewater industry; US-biased with tilt toward small/mid-cap names — higher beta than PHO to the adaptation thesis. Complements PHO with smaller-cap exposure. Use on risk-off flushes for water infrastructure bounce trades. $107.96

Soft-commodity supply-shock expression: drought and deforestation-driven rainfall disruption → crop failures → agri-input and equipment demand surge. Holds fertilizer, irrigation equipment (Lindsay Corp.), seeds/crop protection names. Directly expresses the 'soft-commodity supply shocks' arm of the thesis. Liquid ($500M+ AUM). Trades as a risk asset — size accordingly in risk-off tape. $87.68

Expresses the SHORT side of over-levered coastal financial exposure indirectly: heavy weighting to regional/specialty insurers and financials with coastal real-estate exposure. Use inverse positioning (buy puts or short ETF) as a proxy for coastal insurer stress without having to locate individual small-cap borrow. CAVEAT: Dividend yield creates negative carry for put holders; use sparingly and event-driven only. $12.41

Hard-asset soft-commodity futures expression: drought and rainfall destabilization → corn, wheat, soy, sugar supply shocks → futures repricing. DBA holds diversified agricultural commodity futures. Most direct 'deforestation/drought → commodity supply shock' trade in ETF form. Liquid, low tracking error. Performs in inflationary supply-shock regimes; watch USD for headwind. $29.23

~$12–$13, 52-wk range $8.91–$20.34 — classic capitulation flush from $20 highs. No debt, strong liquidity. Production commenced at Burke Hollow (new ISR mine), resolving prior regulatory delays; Q4 2026 cost improvements expected. Goldman Buy, $16 PT; 9-analyst consensus 'Strong Buy' avg $18. RISK: still pre-meaningful-revenue (negative P/E -60x), unhedged strategy means price exposure to spot uranium which recently retreated to ~$77/lb. Not a balance-sheet disaster but also not yet self-funding — size accordingly. Borrow generally available. $11.62 · 20d +8% · -42% vs 1y-hi · $14M/d

~$14–$16, 52-wk range $10.65–$27.90 — flushed 43% from $27.90 peak. Dual-catalyst: uranium (~$25M Q2 rev, 57% gross margin, $23/lb production cost) PLUS rare-earth mine-to-magnet pivot via ASM acquisition (closed Aug 2026) and $725M govt loan. BMO initiated Outperform, $18 PT; Roth upgraded to Buy. Phase 1B/1C REE expansion targets heavy rare-earth oxide production by late 2027. RISK: Q2 EPS missed badly (-$0.13 vs -$0.03 est), White Mesa Mill in maintenance until Q4 2026/early 2027, so near-term revenue is lumpy. Story-stock with real assets but dilution history — flag. $14.52 · 20d +17% · -48% vs 1y-hi · $10M/d

~$3–$5 range, sub-$1B market cap — cheapest liquid US-listed ISR uranium producer. Texas and Wyoming ISR assets; operational (Rosita, Belle Ayr, North Rosebud). Revenue growing as production ramps. RISK: pre-profitability, thin liquidity vs peers, history of dilutive raises to fund capex — HIGH dilution/reverse-split risk flag. Only for aggressive small-lot speculative entries on nuclear firm-power thesis. Borrow may be tight/costly. $1.22 · 20d +6% · -70% vs 1y-hi · $0M/d

~$20 range (check current price — near bracket ceiling). Mechanism: thermal coal faces structural demand destruction as grid electrification + nuclear firm power displaces coal baseload; AI data center power sourcing is accelerating utility transition away from coal. CAVEAT: ARCH is a metallurgical/thermal hybrid with export optionality — short thesis only activates on peak-demand confirmation. Borrow available but elevated cost given small float. Risk-off tape may actually bid coal as energy-leader; do NOT short into a rising energy tape.

~$60+ (above bracket — flag for size). Pure Appalachian thermal/met coal. Same mechanism as ARCH: electrification + nuclear firm-power erodes baseload coal economics over 3–5 year horizon. More liquid short than ARCH. CAVEAT: currently in Energy sector leadership cohort per risk-off regime — shorting a leader in a risk-off tape is low-probability. Position only on confirmed peak-demand rollover signal. Borrow widely available.

Unleveraged long — direct expression of US electrification thesis. Holds utilities, grid equipment, EV charging, and transmission names. Liquid, diversified; use as core long hedge around single-name trades. U.S. electricity demand projected +35–50% by 2040 per Global X. Not leveraged but highest-purity ETF expression of the grid/electrification bottleneck. $30.87

Unleveraged; tracks Ladenburg Thalmann Electrification Infrastructure Index. Broader than ZAP — includes global electrification infrastructure. 86 holdings, GE Vernova largest weight. Launched April 2025; use as diversified grid-hardware expression alongside ZAP. $39.86

Smart-grid focused; holds transmission, distribution, and grid-management names globally. Expresses the transformer/HV-cable bottleneck thesis where European names (Prysmian, Nexans, NKT) can't be easily bought directly as US-listed under $20. Confirm ticker/name active before trading. $174.33

2x daily inverse on E&P sector — expresses the 'SHORT fossil on peak-demand confirmation' leg of the thesis. Tradeable, liquid, no single-stock borrow needed. DECAY WARNING: hold days, not weeks. Only activate after Energy sector leadership breaks and breadth rolls over. $33.6

Unleveraged but high-beta uranium-miners basket — captures UEC, UUUU, Cameco, and enrichment exposure in one liquid vehicle. 52-week range has been wide and volatile, making it an intraday momentum vehicle. Use as a levered-feel proxy when single-name borrow/liquidity is limited. Holds the fuel-cycle bottleneck thesis without company-specific dilution risk. $54.76

~$19–$21 range — skims the $20 ceiling. Makes Quest and Atkins protein bars/snacks — directly in the GLP-1 consumption upgrade basket. FTI data: ~80% of GLP-1 users consume performance/health nutrition products vs 67% of general population, with protein bars seeing mid-teens consumption increases. SMPL is a real-revenue, positive-EBITDA name (unlike most sub-$20 food 'stories'). Catalysts: GLP-1 user food preference shift accelerating, oral GLP-1 pills (LLY orforglipron approval expected 2026) will expand the addressable user base. RISK: stock has had multiple 'GLP-1 halo' pops — check if already extended. No reverse-split history. Relatively clean balance sheet. Watch for any shelf registration/dilution. $11.75 · 20d +5% · -63% vs 1y-hi · $1M/d

EXCLUDED from long list despite 'healthy food' label — this is exactly the graveyard the thesis warns about. BYND filed Chapter 11 in July 2023 (TTCFQ), BYND itself is pre-bankruptcy with market cap near zero, chronic losses, massive dilution. 'Healthy brand' with no path to profitability. DO NOT LONG. Short is impractical — near-zero borrow, micro-float, extreme squeeze risk. Mention only as a cautionary data point. $12.1 · 20d -34% · -89% vs 1y-hi · $1M/d

Seeks -2x daily performance of the S&P Consumer Staples Select Sector Index — the cleanest levered expression of the 'fragile processed-food incumbent' underweight. Holds KO, PEP, MDLZ, HSY indirectly via index. Use on staples relief bounces when the index is technically extended. Daily reset = decay in sideways tape; size accordingly. Liquid enough for active trading. Best in trending-down staples tape, not a hold. $21.01

Long XLP as a HEDGE/PAIR LEG in risk-off regime (staples lead in risk-off), then fade it relative to picks-and-shovels longs. The pair trade: long SXT/SMPL vs. short XLP captures the WITHIN-sector rotation from processed incumbents to ingredient enablers. XLP itself is not a directional bet — it's the relative vehicle. Liquid, tight spread. $85.26

Holds packaged food names (post-weighting toward revenue growth) — a reasonable proxy for the 'fragile incumbent' basket. Less liquid than XLP but more food-concentrated. Use as a short/put-buying vehicle expressing the thesis that legacy food brand volumes continue to erode under GLP-1 + MAHA dual pressure. Check open interest before sizing options positions. $23.22

Broad health/wellness basket that captures the demand shift from junk food to health products, protein, and GLP-1-adjacent healthcare. Not a true leveraged ETF (1x), but directionally long the GLP-1 beneficiary complex including telehealth, protein brands, and wellness infrastructure. Lower volatility expression. Check AUM/liquidity before entering — smaller ETF with wider spreads. $28.32

Directly targets GLP-1 drug manufacturers, medical device makers, and obesity treatment companies. Captures Eli Lilly, Novo Nordisk, and picks-and-shovels medical device names. Not leveraged but thematically pure. As oral GLP-1 pills expand the addressable market and Medicare begins coverage mid-2026, this basket has structural tailwinds. RISK: already has significant appreciation baked in from the GLP-1 boom; better as a pullback buy than a chase.

~$4.55/share. Fully integrated US injectable CDMO — sterile fill-finish, syringes, vials, cartridges — directly in the GLP-1 supply-chain bottleneck where ~45% of commercial fill-finish volume is still outsourced to CDMOs. Q2 FY2026: $34.2M revenue, $8.6M Adjusted EBITDA (positive turn); 2026 YTD $57.4M revenues. 5 analysts avg 'Buy', 12-month PT $6.83 (+54% from current). Sixth new late-stage pipeline addition in 7 months signals customer wins. RISK FLAGS: Net loss still ongoing (-$34.5M FY2025), no P/E, ~$259M market cap, thin liquidity (~190K avg daily shares), net-loss CDMO with leverage — classic dilution/secondary risk if EBITDA inflection stalls. NOT a hold; a coiled intraday/swing setup on volume confirmation. $4.71 · 20d +6% · -47% vs 1y-hi · $0M/d

~$4.55/share. Deep-flushed MA-tech play that is asymmetrically cheap relative to the structural MA volume shift. 52-week range implies prior forced-selling flush. Clover's AI-driven claims platform is a genuine operational differentiator vs. legacy PBMs. RISK FLAGS: Highly speculative, prior DOJ investigations, persistent losses, thin float, reverse-split history, binary policy risk — this is a LOTTERY TICKET masquerading as a thesis play. Hard-flag: only valid as a small-size intraday scalp on capitulation wicks with tight stops. Do NOT hold overnight without catalyst confirmation. $4.32 · 20d +4% · -20% vs 1y-hi · $1M/d

~$20/share. Value-based care enabler using the HAVEN platform to manage MA costs algorithmically — the exact opposite of a fee-for-service PBM middleman. As United and Humana cede MA membership to control MLRs, Alignment captures those lives via physician group partnerships. Revenue run-rate accelerating; annualized recurring run-rate climbed 26% to $2.2B per recent filings. RISK: Still net-loss; multiple compression risk if MA enrollment broadly contracts under flat-rate pressure. Watch for Q2 membership adds as the trigger. $13.64 · 20d -0% · -44% vs 1y-hi · $2M/d

2x daily inverse the Dow Jones US Health Care Index — catches UNH, CVS, HUM, ELV all in one vehicle. Cleanest intraday expression of a managed-care crack without single-stock borrow risk. Low AUM = liquidity caveat; check daily volume before sizing. Decay risk on multi-day holds. $14.14

3x inverse IBB/biotech — not a perfect MCO short but captures the broader 'pharma/healthcare short' pressure in a risk-off tape. Use only for intraday or very short-term holds; 3x decay is brutal on anything over 2-3 days. Liquid, >$10M daily volume typical. $6.27

3x long XLV — expresses the GLP-1/med-tech toll-road long side of the thesis (XLV is weighted toward device makers, diagnostic firms, and large-cap beneficiaries of GLP-1 volume). Best used when tape stabilizes and MCO noise fades; amplifies the device/enabler long without single-stock dilution risk. $142.21

Spot (1x) inverse candidate — hold via short position or pair against CURE long. IHF is heavily weighted to UNH, CVS, ELV, HUM, CNC — the exact PBM/MCO middleman basket. Lower decay than leveraged products; more suitable for multi-day swing short thesis expression. Liquid, tight spreads. $57.85

FALLBACK NOTE: If pure inverse healthcare ETF liquidity is insufficient on a given day, buying XLV (SPDR Health Care ETF) put spreads targeting the 3-6 week window around the next CMS rate finalization or MCO earnings cycle is the cleanest structural expression of the PBM-crack short with defined risk and no borrow constraint. Tag as 'inverse' via options structure. $45.35

Crossed below its 200DMA (~$9.27) in forced selling; 8-analyst consensus 'Strong Buy' with avg PT $15.50 (+46% from ~$10.60 area). Revenue surged 150% as Pitarrilla mine ramped and metal sales tripled cash flow. H.C. Wainwright PT raised to $8.75→$14 (B. Riley). Risk: negative EPS in prior quarters (miss of -$0.13 vs +$0.03 est. in Q1 2025 pre-ramp), no dividend, dilution history — ONLY trade on volume-flush / intraday capitulation setups where the risk is defined. Not a buy-and-hold. $10.86 · 20d +21% · -23% vs 1y-hi · $21M/d

FY2025 revenue $92.2M vs $66.2M prior year (+39%); Q1 2025 gross profit +352% YoY driven by peso tailwind and cost discipline; record net income $5.6M in Q1. Added to GDXJ and Solactive Global Silver Miners Index (forced passive buy). Sub-$5 price, ~158M diluted shares — HEAVY dilution risk (share count up ~25% in 3 years). Float is small so intraday moves are violent. Flag: no-moat silver producer in Mexico with jurisdiction and FX risk. Only viable as a momentum/capitulation flush trade, not a fundamental hold. $7.46 · 20d +15% · -34% vs 1y-hi · $5M/d

2025 silver production +44% to 1.2M oz; cash balance surged from $20M to $129.8M; added to GDXJ. AISC guidance $30-35/oz vs ~$44+ silver spot — margin improvement is real. BUT: net loss $87.4M in FY2025 (larger dollar loss than 2024's $49M due to metal-linked liabilities mark-to-market); still not FCF positive on ops alone. Reverse-split and dilution risk is elevated for sub-$2 names in this cohort. HIGH RISK — only for momentum/forced-selling setups with tight stops. $5.42 · 20d +13% · -46% vs 1y-hi · $3M/d

The canonical junior miner beta vehicle. Outstanding units down ~22% in 2025 despite ~80% earnings estimate upgrades for the sector — this IS the dumb-money flush that creates the reentry. Junior miners historically amplify gold 2-3x. Liquid (~$2B+ AUM). This is the index-level expression of the long hard-asset thesis without single-stock dilution risk. $128.44

2x daily leveraged long on GDX (senior gold miners). For intraday momentum / capitulation-bounce setups on hard-asset thesis — not a swing hold due to daily reset decay. Use on confirmed volume-reversal days in GDX. Pairs with the fiscal-dominance long: gold miners + rising gold prices + expanding margins = double leverage on the thesis. $188.6

Silver miners express the industrial + monetary dual-use angle. Silver realized price +53% YoY (from $29 to $44.70/oz) flows directly into miner margins. SIL holds EXK, HL, PAAS, First Majestic — the names most levered to silver spot. Lower AUM than GDX/GDXJ so moves are sharper. Use on silver breakout days. $98.68

The liquid -2x daily short on 20+ year Treasuries. Directly expresses the structural anti-fiscal-dominance short. $257M+ AUM, adequate daily volume. Decays on range-bound bonds — only outperforms in trending yield-up regimes. Best used when 30y yield is breaking above key resistance. Pairs cleanly with the miner longs as a book hedge. $38.31

-3x daily exposure to long Treasuries. $185M+ AUM, ~$37M in average daily dollar volume — more liquid intraday than TBT on a per-dollar-traded basis. Maximum leverage expression of the long-bond short thesis. Severe NAV decay risk if held multi-day in a choppy rate environment; strictly an intraday or short-swing vehicle. Use on days when 30y auction tails or fiscal headlines break. $42.67

Only fully licensed conventional uranium mill in the US (White Mesa, Utah) doubling as the domestic REE separation hub. Q2 2026 revenue $25M (badly missed $44.15M consensus — flag: HMS segment dropped out YoY, REE segment $0 revenue H1 2026). BUT catalysts are stacking: terbium oxide qualified by Japan's largest permanent magnet maker (Aug 2026); acquiring VAC (magnet metals/alloys) for ~$1.9B in a mine-to-magnet vertical; heavy REE (Tb/Dy) circuit expansion targeted end-2027. B. Riley Buy PT $25, Roth Capital upgraded to Buy PT $16. Stock likely flushed on earnings miss + dilution from VAC acquisition (Aug 6 SEC shelf filing). Risk: meaningful dilution from $1.9B deal; REE segment is still pre-revenue; execution on integration. Watch for forced-selling capitulation as a low-risk entry. $14.56 · 20d +17% · -47% vs 1y-hi · $11M/d

US government took a 10% equity stake + $1.6B strategic package ($1.3B CHIPS facility debt + $277M grant) as of Jan 2026 — the most explicit 'policy backstop' in the sector. Stillwater, Oklahoma magnet plant targeting commercial-scale NdFeB sintered magnet production in 2026 (commissioning final stages as of Jan 2026). Acquired Less Common Metals (UK) for $100M cash + 6.74M shares to secure feedstock independent of China. Round Top heavy REE deposit (Texas) — dysprosium, terbium — earliest mine production 2028. Highest-risk/reward on the list: pre-mine-revenue, story heavily dependent on government support continuing and magnet plant ramp executing on schedule. Flag: dilution from LCM acquisition shares; no upstream revenue yet; binary on Stillwater ramp. Only for confirmed intraday setups, not a hold. $17.61 · 20d +3% · -54% vs 1y-hi · $30M/d

Pure-play counter-drone + critical infrastructure security. Received initial $68M order under a multi-year $140M strategic military engineering program (Q4 2026 delivery). Subsidiary Sentrycs deployed across all 16 FIFA World Cup 2026 host cities (US/Canada/Mexico) — proof of commercial doctrine adoption. FY26 revenue guidance raised to $525–$550M. Current price ~$7, 52-wk range $4.90–$15.28 — sitting near the lower third of its range. Oppenheimer PT $18, kept Outperform post-earnings. FLAG: Q2 EPS -$0.19 vs -$0.07 estimate — significant miss; still burning cash (H1 2026 cash ~$658K). Risk: heavily dependent on military contract timing/delivery, dilution likely to fund ops. 'Security > efficiency' theme is direct — counter-drone is now a mandated procurement category per doctrine, not discretionary. Good capitulation candidate in risk-off tape. $7.35 · 20d -17% · -48% vs 1y-hi · $66M/d

~$5.20/share, ~$708M market cap. US rare earth project (niobium/scandium/titanium, Nebraska) with 2026 DoD-funded drilling campaign (final assay results being used to update mine plan for pending Ex-Im Bank financing application). On the 2025 US Critical Minerals list. Catalysts are timing/financing dependent — needs Ex-Im Bank approval and construction capital before earning operating premium. Binary risk: no production, no revenue, no guaranteed financing close. Flag: classic story-stock graveyard candidate — include only on confirmed DoD/Ex-Im catalyst, not as a hold. $4.08 · 20d -19% · -65% vs 1y-hi · $1M/d

Speculative tier rare earth/feedstock recycling story — rare earth exposure is tied to platform development and corporate structure (ReElement relationship) rather than current production. No meaningful rare earth revenue; highly dilutive structure. Mechanism: as the sector rotates to names with actual production catalysts (UUUU, USAR), capital exits platform/story names. Caveat: extremely low float, very hard borrow, violent squeeze risk — this is a short only for experienced traders with confirmed borrow; treat as a fade-the-rip, not a structural short. $2.42 · 20d +13% · -65% vs 1y-hi · $1M/d

China EV / consumer tech exposed to China mineral coercion escalation from the other side: XPEV's supply chain depends on Chinese REE magnet inputs that are now being weaponized as export controls tighten. Mechanism: China mineral export controls raise XPEV's input costs while simultaneously strengthening the US domestic REE buildout narrative — it's the mirror trade. Also directly hit by US-China trade fragmentation. Caveat: ADR borrow can be inconsistent; geopolitical news can cause violent squeezes — use tight stops, size small. $11.08 · 20d -6% · -61% vs 1y-hi · $16M/d

Largest critical minerals ETF by AUM (~$7.3B), providing direct equity exposure to copper miners globally. Expresses the 'copper as master metal of electrification + fragmentation' leg with real liquidity and diversification across producers. Use as the core, less-volatile copper long while individual names like ERO provide higher-beta point exposure. $91.2

~$2.3B AUM. Tracks companies in production, refining, and recycling of rare earth and strategic metals — direct expression of the China coercion / Western supply chain buildout thesis. Includes UUUU, MP Materials, Lynas. Liquid enough for active traders. Note: includes some Chinese-listed names, so is not a pure ex-China play. $76.09

Launched April 14, 2026 — newest and most targeted instrument for the 'non-China REE supply chain' thesis. Tracks companies domiciled outside China; largest positions are Lynas Rare Earths and MP Materials as of Aug 2026. Smaller/less liquid than REMX but offers purer Western-supply-chain exposure without Chinese producer contamination. Best for the 'policy-backed domestic REE buildout' sub-thesis. $17.62

The liquid, mainstream defense long. Expresses the NATO 5% GDP / $1.15T NDAA FY2027 rearmament thesis through diversified US defense prime and sub-prime exposure. Not a sub-$20 vehicle, but the anchor hedge for the thesis if the tape reverses risk-on — pairs well with the small-cap longs to size the thesis proportionally across market-cap tiers. $224

Inverse expression of China mineral coercion escalation and trade fragmentation. If China tightens REE/gallium/germanium export controls further and US retaliates with tariff/investment escalation, Chinese equity indices get hit. YANG is the blunt 3x inverse instrument for that scenario. Use only as a tactical spike trade on escalation headlines — 3x decay makes it a hold-overnight-max vehicle. High volatility, high decay cost. $28.21

Security robotics-as-a-service (RaaS) pure play; machines are RENTED not sold — direct expression of 'rent humanoids, don't own them' thesis. FY2025 revenue $11.34M +4.9% YoY; Q2 2025 EPS beat estimate by $0.24. 5-year CMU collaboration + National Security Robotics Lab announced April 2026 = credentialing catalyst. Event Risk acquisition positions for accelerated growth in 2026. Stock ~$1.40-$3.50 range (deeply flushed -62% past year) vs. analyst avg PT $15.33 (3 analysts, 'Strong Buy'). RISK: losses widened to -$33.8M in 2025; revenue growth tepid (5%); reverse-split history; Class A/B share structure limits governance; borrow can be thin at these prices — confirm short interest/borrow before trading. Capitulation candidate in risk-off flush. $1.33 · 20d -15% · -82% vs 1y-hi · $0M/d

Sidewalk delivery robot RaaS; fleet scaled to 2,000 robots by end 2025 across 20 cities; DoorDash partnership revenue +50% sequentially in Q2 2026; signed 7 multiyear hospital contract extensions (Diligent Robotics acquisition adds healthcare vertical). Q2 2026 revenue $3.2M +404% YoY. BUT: FY2026 guidance cut from ~$26M to $9-10M due to Uber Eats volume shortfall — this is the key risk/setup. Stock has been hammered on guidance cut = potential capitulation candidate if indiscriminate selling continues. SEVERE DILUTION RISK: $150M ATM equity offering filed; net loss widened 271% in Q1 2026 to -$49M; insiders net sold $8M last 12mo; ~86M shares outstanding. At ~$9 this is a trader's name only — must size tiny, use stops. Do NOT hold through dilution events. $4.76 · 20d -16% · -73% vs 1y-hi · $2M/d

MECHANISM: Q1 FY2025 revenue $40K — effectively zero revenue while burning cash; raised $54.5M in dilutive offering to survive. European OEM radar orders for 2028 vehicle platforms mean revenue is 2-3 years away at minimum. Classic 'story stock' with no near-term commercial catalyst. 2025 revenue guidance only $2-5M. CAVEAT: Small float + heavy retail interest = violent short squeezes possible; borrow can be expensive or unavailable; size accordingly and use hard stops. Better as a fade-the-rip on hype days than a structural short at current prices. $0.65 · 20d -8% · -76% vs 1y-hi · $0M/d

MECHANISM: Industrial 3D printing for manufacturing; revenue stagnant/declining, heavy losses, no clear path to profitability, and reshoring construction spend rolling over removes near-term catalyst. Competes against better-capitalized players. Dilution risk from repeated equity raises. CAVEAT: Low float + low price = squeeze risk on any positive PR; borrow may be unavailable or hard — treat as fade-the-pop only, not a structural short. Verify current price and borrow rate before entry.

2x daily leverage on robotics/automation index — captures the labor-scarcity automation thesis with amplification. 1.34% expense ratio; daily rebalancing causes compounding decay on multi-day holds. STRICTLY intraday or 1-3 day swing use only; compounding decay kills long-term holders. Use on confirmed tape-up days with breadth confirmation. $21.48

Non-leveraged but most liquid pure-robotics ETF ($25B+ total sector AUM); focused on industrial robotics manufacturers (Keyence, Fanuc, ABB) plus AI automation. 29% top-3 concentration; ~50%+ non-US including Japan. Expresses automation/labor-scarcity thesis with built-in Japan exposure (itself a demographic-crisis automation leader). Use as core long on pullbacks; less volatile than UBOT for multi-day holds. $35.09

91 holdings, equal-weight, spreads across small- and mid-cap automation and component makers — widest diversification across the automation value chain. Top-10 only 17.59% of portfolio. 0.95% expense ratio (highest of peer group) is the cost of diversification. Best expression of 'picks-and-shovels' automation thesis without concentration in a few megacaps. Liquid enough for swing trading. $78.96

~240 small-cap Indian stocks; contrarian India demographic-dividend play that has de-rated significantly. Purer domestic India exposure vs. INDA (dominated by Reliance/HDFC megacaps). Weak-dollar tailwind amplifies INR-denominated returns. Coiled near support ~$71-72 with MA buy signals as of late August 2026. Core ETF vehicle for the EM demographic-dividend leg of the thesis. $71.94

Broad SE Asia exposure (Indonesia, Malaysia, Philippines, Singapore, Thailand) — the 'China+1' labor-abundance demographic-dividend markets (Vietnam, Indonesia, Philippines are primary beneficiaries of manufacturing relocation). Smaller AUM than India ETFs so watch bid-ask spread. Expresses the non-India EM leg of the thesis; weak dollar is a structural tailwind. Use as satellite position alongside SMIN for full China+1 coverage. $21.52